Global economic burden of schizophrenia: a systematic review

Huey Yi Chong,1 Siew Li Teoh,1 David Bin-Chia Wu,1 Surachai Kotirum,1 Chiun-Fang Chiou,2 Nathorn Chaiyakunapruk1,3–5 1School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; 2Janssen Pharmaceutical Companies Asia Pacific, Singapore; 3Center of Pharmaceutical Outcomes Research...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chong HY, Teoh SL, Wu DBC, Kotirum S, Chiou CF, Chaiyakunapruk N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	schizophrenia economic burden cost of illness systematic review Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5f01463afa3342f89aa22ac5c9348a34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f01463afa3342f89aa22ac5c9348a34
record_format	dspace
spelling	oai:doaj.org-article:5f01463afa3342f89aa22ac5c9348a342021-12-02T02:17:17ZGlobal economic burden of schizophrenia: a systematic review1178-2021https://doaj.org/article/5f01463afa3342f89aa22ac5c9348a342016-02-01T00:00:00Zhttps://www.dovepress.com/global-economic-burden-of-schizophrenia-a-systematic-review-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Huey Yi Chong,1 Siew Li Teoh,1 David Bin-Chia Wu,1 Surachai Kotirum,1 Chiun-Fang Chiou,2 Nathorn Chaiyakunapruk1,3–5 1School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; 2Janssen Pharmaceutical Companies Asia Pacific, Singapore; 3Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; 4School of Pharmacy, University of Wisconsin, Madison, WI, USA; 5School of Population Health, University of Queensland, Brisbane, Australia Background: Schizophrenia is one of the top 25 leading causes of disability worldwide in 2013. Despite its low prevalence, its health, social, and economic burden has been tremendous, not only for patients but also for families, caregivers, and the wider society. The magnitude of disease burden investigated in an economic burden study is an important source to policymakers in decision making. This study aims to systematically identify studies focusing on the economic burden of schizophrenia, describe the methods and data sources used, and summarize the findings of economic burden of schizophrenia. Methods: A systematic review was performed for economic burden studies in schizophrenia using four electronic databases (Medline, EMBASE, PsycINFO, and EconLit) from inception to August 31, 2014. Results: A total of 56 articles were included in this review. More than 80% of the studies were conducted in high-income countries. Most studies had undertaken a retrospective- and prevalence-based study design. The bottom-up approach was commonly employed to determine cost, while human capital method was used for indirect cost estimation. Database and literature were the most commonly used data sources in cost estimation in high-income countries, while chart review and interview were the main data sources in low and middle-income countries. Annual costs for the schizophrenia population in the country ranged from US$94 million to US$102 billion. Indirect costs contributed to 50%–85% of the total costs associated with schizophrenia. The economic burden of schizophrenia was estimated to range from 0.02% to 1.65% of the gross domestic product. Conclusion: The enormous economic burden in schizophrenia is suggestive of the inadequate provision of health care services to these patients. An informed decision is achievable with the increasing recognition among public and policymakers that schizophrenia is burdensome. This results in better resource allocation and the development of policy-oriented research for this highly disabling yet under-recognized mental health disease. Keywords: schizophrenia, economic burden, cost of illness, systematic reviewChong HYTeoh SLWu DBCKotirum SChiou CFChaiyakunapruk NDove Medical Pressarticleschizophreniaeconomic burdencost of illnesssystematic reviewNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 357-373 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia economic burden cost of illness systematic review Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenia economic burden cost of illness systematic review Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Chong HY Teoh SL Wu DBC Kotirum S Chiou CF Chaiyakunapruk N Global economic burden of schizophrenia: a systematic review
description	Huey Yi Chong,1 Siew Li Teoh,1 David Bin-Chia Wu,1 Surachai Kotirum,1 Chiun-Fang Chiou,2 Nathorn Chaiyakunapruk1,3–5 1School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; 2Janssen Pharmaceutical Companies Asia Pacific, Singapore; 3Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; 4School of Pharmacy, University of Wisconsin, Madison, WI, USA; 5School of Population Health, University of Queensland, Brisbane, Australia Background: Schizophrenia is one of the top 25 leading causes of disability worldwide in 2013. Despite its low prevalence, its health, social, and economic burden has been tremendous, not only for patients but also for families, caregivers, and the wider society. The magnitude of disease burden investigated in an economic burden study is an important source to policymakers in decision making. This study aims to systematically identify studies focusing on the economic burden of schizophrenia, describe the methods and data sources used, and summarize the findings of economic burden of schizophrenia. Methods: A systematic review was performed for economic burden studies in schizophrenia using four electronic databases (Medline, EMBASE, PsycINFO, and EconLit) from inception to August 31, 2014. Results: A total of 56 articles were included in this review. More than 80% of the studies were conducted in high-income countries. Most studies had undertaken a retrospective- and prevalence-based study design. The bottom-up approach was commonly employed to determine cost, while human capital method was used for indirect cost estimation. Database and literature were the most commonly used data sources in cost estimation in high-income countries, while chart review and interview were the main data sources in low and middle-income countries. Annual costs for the schizophrenia population in the country ranged from US$94 million to US$102 billion. Indirect costs contributed to 50%–85% of the total costs associated with schizophrenia. The economic burden of schizophrenia was estimated to range from 0.02% to 1.65% of the gross domestic product. Conclusion: The enormous economic burden in schizophrenia is suggestive of the inadequate provision of health care services to these patients. An informed decision is achievable with the increasing recognition among public and policymakers that schizophrenia is burdensome. This results in better resource allocation and the development of policy-oriented research for this highly disabling yet under-recognized mental health disease. Keywords: schizophrenia, economic burden, cost of illness, systematic review
format	article
author	Chong HY Teoh SL Wu DBC Kotirum S Chiou CF Chaiyakunapruk N
author_facet	Chong HY Teoh SL Wu DBC Kotirum S Chiou CF Chaiyakunapruk N
author_sort	Chong HY
title	Global economic burden of schizophrenia: a systematic review
title_short	Global economic burden of schizophrenia: a systematic review
title_full	Global economic burden of schizophrenia: a systematic review
title_fullStr	Global economic burden of schizophrenia: a systematic review
title_full_unstemmed	Global economic burden of schizophrenia: a systematic review
title_sort	global economic burden of schizophrenia: a systematic review
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/5f01463afa3342f89aa22ac5c9348a34
work_keys_str_mv	AT chonghy globaleconomicburdenofschizophreniaasystematicreview AT teohsl globaleconomicburdenofschizophreniaasystematicreview AT wudbc globaleconomicburdenofschizophreniaasystematicreview AT kotirums globaleconomicburdenofschizophreniaasystematicreview AT chioucf globaleconomicburdenofschizophreniaasystematicreview AT chaiyakunaprukn globaleconomicburdenofschizophreniaasystematicreview
_version_	1718402598332006400

Global economic burden of schizophrenia: a systematic review

Ejemplares similares